Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
SDĚLENÍ
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx mění x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. x x. 46/2008 Sb. x. s. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 97/2012 Xx. x. x. o Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že dne 12. xxxxxxxxx 2012 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx schválení xxxxxx xxxxx Přílohy X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx1).
X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky.
Nové xxxxx Přílohy X xxxxxxxxx v xxxxxxxx x souladu s xxxxxxx 34 xxxx. 3 Xxxxxx dne 1. ledna 2013 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx platné xx 1. xxxxx 2012 x xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Anglické xxxxx Přílohy X x xxxx xxxxxxx xx českého xxxxxx xx xxxxxxxxx současně.
1) Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu přijatá xxx 19. října 2005 v Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.
PŘÍLOHA X
XXXXXX XXXXXXXXXX LÁTEK X XXXXX XXXXXXX XXX ROK 2013
XXXXXXX ANTIDOPINGOVÝ KODEX
Xxxxxx od 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx látky budou xxxxxxxxxx xx "Specifické xxxxx" xxxxx xxxxx xx skupin X1, X2, X4.4, S4.5 x S6(a) x Xxxxxxxxxx xxxxx X1, X2 x M3.
|
LÁTKY X XXXXXX XXXXXXXX XXXXX
(XXX SOUTĚŽI X XXXX XXXXXX)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx stále.
S1. XXXXXXXXXX LÁTKY
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; norklostebol; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); xxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, xxxxx xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x jejich xxxxxxxxxx x xxxxxxx, xxx ne s xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
|
|
5α-androstan-3α,17β-diol
|
|
|
5α-androstan-3β,17α-diol
|
epi-dihydrotestosteron
|
|
5α-androstan-3β,17β-diol
|
epitestosteron
|
|
androst-4-en-3α,17α-diol
|
3α-hydroxy-5αandrostan-17-on
|
|
androst-4-en-3α,17β-diol
|
3β-hydroxy-5αandrostan-17-on
|
|
androst-5-en-3β,17α-diol
|
7α-hydroxy-DHEA
|
|
androst-5-en-3α,17α-diol
|
7β-hydroxy-DHEA
|
|
androst-5-en-3α,17β-dioI
|
7-keto-DHEA
|
|
androst-5-en-3β,17α-diol
|
19-norandrosteron
|
|
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Klenbuterol, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, ale xx x xxxxxxxx xxxxx xx ně.
|
Pro xxxxx xxxxxxx této xxxxx: * "exogenní" xx xxxxxxxx k xxxxx, xxxxxx tělo xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k látce, xxxxxx může xxxx xxxxxxxxxx xxxxxxxxx.
|
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX LÁTKY
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx xxxxxx (LH) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx růstový xxxxxx (XXX), insulinu xxxxxxx xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx růstové xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx růstové xxxxxxx ovlivňující xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx x xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, regenerativní xxxxxxxx nebo ovlivňující xxxx svalových xxxxxx;
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-), xxxx xxxxxxxx kromě xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) a salmeterolu xxxxx jsou podány x xxxxxxxx x xxxxxxx s xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx považována xx xxxxxxxxx terapeutické xxxxxxx, xxx xxxx považována xx xxxxxxxxx laboratorní xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx byl xxxxxxxx xxxxxxxx terapeutické xxxxxxxxx xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. HORMONOVÉ X XXXXXXXXXXX MODULÁTORY
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx aromatáz, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Selektivní xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, ale xx s omezením xxxxx na xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
4. Xxxxx xxxxxxxxxxxx xxxxxx myostatinu xxxxxx xxxxxxxxxx myostatinu, xxx xx x xxxxxxxx xxxxx na xx.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Insuliny;
x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Activated Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. XXXXXXXXX X OSTATNÍ XXXXXXXXX XXXXX
Xxxxxxxxx látky xxxx zakázané. Zahrnují:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxxx xxxxxxxxxxxx účinky. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx a xxxxxxxxx xxxxxx dorzolamidu a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Soutěž) jakéhokoliv xxxxxxxx látky se xxxxxxxxxx prahovým xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x té, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXXX X KRVÍ X XXXXXXXX KOMPONENTAMI
Zakázané xx následující:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx podobných produktů xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx zvyšování xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (např.krevní xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx pouze xx xx. Xxxxxxxxxxxx xxxxxxxx zakázána xxxx.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace s xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxx, nebo pokus x xxxxxx, xx xxxxxx porušit integritu x xxxxxxxx Xxxxxx xxxxxxxxxx při Dopingové xxxxxxxx xx xxxxxxxx. Xx zahrnuje xxxxxx x/xxxx xxxxxx (např. xxxxxxxxxx) xxxx, xxx xx s omezením xxxxx xx ně.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx nebo klinických xxxxxxxxxxxxx metod.
M3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx buněk;
|
XXXXX X METODY XXXXXXXX XXX SOUTĚŽI
|
Xxxxx xxxxxxxxx X0 xx X5 x X1 xx M3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx zakázané x následující xxxxxxx:
XXXXXXXX XXXXX
S6. XXXXXXXXXXX
Všechna stimulancia xxxxxx všech jejich xxxxxxxxxx optických xxxxxxx (xxxx. x- a x-) jsou xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2013*.
Xxxxxxxxxxx zahrnují:
(a) Xxxxxxxxxxxx stimulancia:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, xxxxxxxxx, dimethylamfetamin, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, fenfluramin, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (karfedon), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.
Stimulancium, xxxxx xxxx xxxxxxxx uvedeno x tomto odstavci, xx Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Adrenalin**, xxxxx***, xxxxxxx****, etamivan, xxxxxxxxx, xxxxxxxxxxx, fenkamfamin, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) nejsou považovány xx Zakázané látky.
** Lokální xxxxxx xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) xxxx xxxx podání xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx než 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx a xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 mikrogramů x 1 xx xxxx.
***** Xxxxxxxxxxxxx je xxxxxxx, xxxxx jeho xxxxxxxxxxx v moči xx vyšší xxx 150 mikrogramů xx xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, dextromoramid, diamorfin(heroin), xxxxxxxx x jeho xxxxxxxx, hydromorfon, metadon, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, konopí a xxxxxxxxx) xxxx syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) a xxxxxxxxxxxxxx (např. "Xxxxx" /XXX018, XXX073/ x XX-210) jsou zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X URČITÝCH SPORTECH
|
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx rozborem xxxx. Xxxxxxx hodnota xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 g/l.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx sport (XXX)
∙ Xxxxx xxxxxxxxxx (UIM)
P2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx určeno, beta-blokátory xxxx xxxxxxxx xxxxx Xxx Soutěži x xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx také Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx lyžích x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x snowboard X-xxxxx x "xxx xxx"
∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx soutěž)
∙ Xxxxx (XXX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, atenolol, xxxxxxxxx, xxxxxxxxxx, bunolol, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, ale xx x omezením xxxxx xx xx.
Xxxxxxxxx
Xxxxxx předpis x. 98/2013 Xx. m. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.